Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Nature ; 2020 Jul 29.
Article in English | MEDLINE | ID: covidwho-691301

ABSTRACT

The novel Coronavirus SARS-CoV-2 causes a respiratory illness called COVID-19 leading to a pandemic. An effective preventive vaccine against this virus is urgently needed. As the most critical step during infection, SARS-CoV-2 uses its Spike protein receptor-binding domain (S-RBD) to engage with the host cell receptor angiotensin-converting enzyme 2 (ACE2)1,2. Here we showed that a recombinant vaccine comprising residues 319-545 of the S-RBD could induce a potent functional antibody response in the immunized mice, rabbits and non-human primates (Macaca mulatta) as early as 7 or 14 days after a single dose injection. The sera from the immunized animals blocked RBD binding to ACE2 expressed on the cell surface and neutralized the infection by SARS-CoV-2 pseudovirus and live SARS-CoV-2 in vitro. Importantly, the vaccination also provided protection in non-human primates from SARS-CoV-2 challenge in vivo. The elevated RBD-specific antibodies were also found in the sera from patients with COVID-19. Several immune pathways and CD4 T lymphocytes were implicated in the induction of the vaccine antibody response. Our finding highlights the importance of the RBD domain in the SARS-CoV-2 vaccine design and provides the rationale for the development of a protective vaccine through the induction of antibody against the RBD domain.

2.
Curr Res Transl Med ; 68(3): 111-118, 2020 08.
Article in English | MEDLINE | ID: covidwho-622221

ABSTRACT

The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.


Subject(s)
Coronavirus Infections/prevention & control , Delivery of Health Care/organization & administration , Hematologic Neoplasms/therapy , Immunotherapy, Adoptive , Infection Control/organization & administration , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Receptors, Antigen, T-Cell/immunology , Betacoronavirus/physiology , Coronavirus Infections/epidemiology , Delivery of Health Care/methods , Delivery of Health Care/standards , Delivery of Health Care/trends , Hematologic Neoplasms/epidemiology , Humans , Immunotherapy, Adoptive/methods , Immunotherapy, Adoptive/trends , Infection Control/methods , Infection Control/standards , Infection Control/trends , Pneumonia, Viral/epidemiology , Preventive Health Services/methods , Preventive Health Services/organization & administration , Preventive Health Services/standards , Preventive Health Services/trends
3.
Exp Biol Med (Maywood) ; 245(13): 1096-1103, 2020 07.
Article in English | MEDLINE | ID: covidwho-615437

ABSTRACT

IMPACT STATEMENT: The impact of the COVID-19 pandemic has been worldwide, and clinicians and researchers around the world have been working to develop effective and efficient methods for early detection as well as monitoring of the disease progression. This minireview compiles the various agency and expert recommendations, along with results from studies published in numerous countries, in an effort to facilitate the research in imaging technology development to benefit the detection and monitoring of COVID-19. To the best of our knowledge, this is the first review paper on the topic, and it provides a brief, yet comprehensive analysis.


Subject(s)
Coronavirus Infections/diagnostic imaging , Lung/diagnostic imaging , Pneumonia, Viral/diagnostic imaging , Tomography, X-Ray Computed , Betacoronavirus , Clinical Laboratory Techniques , Coronavirus Infections/diagnosis , Disease Progression , Humans , Pandemics , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL